Showing results (191-200 of 536) with videos related to
Sort By:
Pageof 54
Molecules (Basel, Switzerland)|June 12, 2026
Mechanism of Mutation in G Protein-Gated Inwardly Rectifying K<sup>+</sup> Channel in Familial Hyperaldosteronism-Type III: Residue Fluctuations and Conformational InstabilityAsmaa S AbuMaziad, Julia J Liang, Alex N O Logothetis, et al.Food & Function|June 27, 2015
RNA sequencing supports distinct reactive oxygen species-mediated pathways of apoptosis by high and low size mass fractions of Bay leaf (Lauris nobilis) in HT-29 cellsAnnabelle L Rodd, Katherine Ververis, Dheeshana Sayakkarage, et al.Diabetes Technology & Therapeutics|August 8, 2002
Combination antihypertensive therapy in the treatment of diabetic nephropathyGeoffrey Boner, Zemin Cao, Mark E CooperCurrent Hypertension Reports|February 3, 2012
What are new avenues for renal protection, in addition to RAAS inhibition?Shinji Hagiwara, Phillip Kantharidis, Mark E CooperIdrugs : the Investigational Drugs Journal|November 25, 2004
Treatment for diabetic nephropathy - a review of the recent patent literatureRiccardo Candido, Bruno Fabris, Mark E CooperFrontiers in Bioscience (Scholar Edition)|January 4, 2011
Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunctionJudy B de Haan, Mark E CooperDiabetologia|April 25, 2015
50 years forward: mechanisms of hyperglycaemia-driven diabetic complicationsNicholas D F Russell, Mark E CooperThe Journal of Clinical Investigation|November 3, 2025
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesityMark E Cooper, Daniël H van RaalteCurrent Pharmaceutical Design|July 13, 2013
MicroRNA as biomarkers and regulator of cardiovascular development and diseaseShinji Hagiwara, Phillip Kantharidis, Mark E CooperSeminars in Nephrology|September 12, 2002
Role of nephrin in renal disease including diabetic nephropathyMark E Cooper, Peter Mundel, Geoffrey BonerPageof 54